Previous 10 | Next 10 |
home / stock / cara / cara articles
U.S. stocks traded mixed toward the end of trading, with the S&P 500 edging higher on Thursday. The Dow traded down 0.21% to 38,629.82 while th...
Shares of Signet Jewelers Limited (NYSE:SIG) fell sharply during Thursday's session following mixed first-quarter earnings including an 8.9% d...
U.S. stocks traded mixed midway through trading, with the Dow Jones index dipping by more than 200 points on Thursday. The Dow traded down 0.60% to...
Shares of Broadcom Inc. (NASDAQ:AVGO) rose sharply in today's pre-market trading after the company posted stronger-than-expected results for i...
STAMFORD, Conn., May 06, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a development-stage biopharmaceutical company leading ...
STAMFORD, Conn., April 02, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a development-stage biopharmaceutical company leadin...
STAMFORD, Conn., March 07, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a development-stage biopharmaceutical company leadin...
Shares of SOPHiA GENETICS SA (NASDAQ: SOPH) fell sharply during Tuesday’s session after the company reported worse than expected fourth-quar...
Shares of Paymentus Holdings, Inc. (NYSE: PAY) rose sharply in today’s pre-market trading after the company reported better-than-expected fo...
News, Short Squeeze, Breakout and More Instantly...
Cara Therapeutics Inc. Company Name:
CARA Stock Symbol:
NASDAQ Market:
Cara Therapeutics Inc. Website:
– Study achieved primary endpoint of Worst Itch-Numeric Rating Scale score change from baseline at Week 8 (p=0.001) – – Onset of action seen at Week 1 and sustained through Week 8 – – Statistical significance achieve...
KORSUVA™ (difelikefalin) injection U.S. commercial launch began in April 2022 and is tracking to expectation Kapruvia ® (difelikefalin) approved by European Commission for the treatment of moderate-to-severe pruritus associated with chronic kidney disease...
STAMFORD, Conn., May 03, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President an...